Stockholm (HedgeNordic) – Rhenman & Partners is expanding its five-person investment team with the hiring of Amennai Beyeen as a biopharma analyst. He joins from global healthcare company Novartis.
“We are very happy to welcome Amennai to Rhenman & Partners,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners. “Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”
“We are very happy to welcome Amennai to Rhenman & Partners.”
Amennai Beyeen has worked for about 12 years at Novartis, focusing on the development and launch of new drugs. He also holds a doctorate in neuroimmunology from Karolinska Institutet in Stockholm. Beyeen will join the five-person investment team running the healthcare-focused equity hedge fund Rhenman Healthcare Equity L/S. He will have a particular focus on biopharma companies and the development of new drugs and treatments.
“It is very exciting to start at Rhenman & Partners,” Amennai Beyeen comments on joining the Swedish healthcare-focused asset manager. “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years,” he continues. “I look forward to joining this competent team and contributing with my experience from the life science sector.”
Rhenman & Partners Asset Management has been running its long-biased equity hedge fund with an exclusive focus on healthcare since mid-2009, delivering an annualized return of 17.3 percent through November 2022. The fund’s main share class (IC1 EUR) edged down 1.6 percent in the first 11 months of this year. Rhenman Healthcare Equity L/S oversees €923 million in assets under management.